Biologics APIs

Alliance for mRNA Medicines Officially Launched in Germany

November 06, 2023

The Alliance for mRNA Medicines (AMM) was officially launched at the 11th International mRNA Health Conference in Berlin, Germany.

Aragen to Establish $30 Million Biomanufacturing Facility in India

November 02, 2023

As part of a $30 million investment, Aragen is setting up a new biologics manufacturing facility in Bangalore, India.

Spark Therapeutics Partners with SpliceBio on a Gene Therapy for Eye Disease

October 18, 2023

Spark Therapeutics and SpliceBio have formed a collaboration to develop a gene therapy that can treat an inherited retinal disease.

CIRM Picks Forge Biologics as AAV Manufacturing Partner

October 18, 2023

The California Institute for Regenerative Medicine has partnered with Forge Biologics, which will manufacture AAVs to help accelerate gene therapy programs in California.

Cellares Expands Agreement with Bristol Myers Squibb for Second CAR-T Program

October 13, 2023

Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb.

Salipro Biotech and Icosagen to Collaborate on Antibody Discovery

October 12, 2023

Salipro Biotech and Icosagen have entered into a multi-target collaboration to discover and characterize monoclonal antibodies.

Roche to Develop Two Novel RNA-targeted Programs from Ionis for CNS Diseases

October 11, 2023

Roche will gain exclusive worldwide rights to develop, manufacture, and commercialize Ionis’ investigational RNA-based therapeutic candidates for Alzheimer's and Huntington's disease.

Lilly Receives Complete Response Letter from FDA for Lebrikizimab

October 09, 2023

Eli Lilly and Company has received a complete response letter from FDA for its anti-dermatitis biologic therapeutic, lebrikizumab.

Dyadic and bYoRNA Collaborate on Production of mRNA

September 26, 2023

The companies plan on targeting the production of abundant, low-cost messenger RNA from C1-cells.

EMA Committee Issues Positive Opinion on Sandoz’ Biosimilar Trastuzumab

September 18, 2023

The EMA’s Committee for Medicinal Products for Human Use has given a positive opinion on Sandoz’ biosimilar trastuzumab for breast and gastric cancer.